Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 38 | SFEBES2015 | Next issue

Society for Endocrinology BES 2015

Edinburgh, UK
02 Nov 2015 - 04 Nov 2015

Card image cap
2-4 November 2015, Edinburgh, UK Further information

Poster Presentations


A role for 11C-methionine PET/CT-MRI in the management of de novo and residual acromegaly
1Wellcome Trust–MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, UK; 2Department of Medical Physics, Addenbrooke’s Hospital, Cambridge, UK; 3Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, UK; 4Department of Endocrinology, Barts and London School of Medicine, London, UK; 5Department of Endocrinology, King’s College Hospital, London, UK; 6Department of Endocrinology, Royal Devon and Exeter Hospital, Exeter, UK; 7Department of Endocrinology, New Cross Hospital, Wolverhampton, UK; 8Department of Endocrinology, Leicester Royal Infirmary, Leicester, UK; 9Department of Radiation Oncology, Addenbrooke’s Hospital, Cambridge, UK; 10Department of Radiology, Addenbrooke’s Hospital, Cambridge, UK; 11Department of Neurosurgery, Addenbrooke’s Hospital, Cambridge, UK.
The effect of AIP on AHR transcriptional activity: implications for AIP mutations pathogenicity
1Department of Endocrinology, Barts and the London School of Medicine, William Harvey Research Institute, Centre for Endocrinology, Queen Mary University of London, London, UK; 2Department of Endocrinology, C.I. Parhon National Institute of Endocrinology, Carol Davila University of Medicine, Bucharest, Romania.
Investigation of the invasive phenotype of AIP-mutated pituitary adenomas
1Barts and the London School of Medicine, Department of Endocrinology, QMUL, London, UK; 2Barts and the London School of Medicine, Barts Cancer Institute, QMUL, London, UK.
The founder R304* AIP mutation is prevalent in Irish acromegaly and gigantism patients as well as in the general population of Ireland
1Department of Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK; 2Department of Endocrinology, “C. Davila” University of Medicine and Pharmacy and C.I Parhon National Institute of Endocrinology, Bucharest, Romania; 3Research Department of Genetics, Evolution and Environment, University College London, London, UK; 4Department of Medical Genetics, Belfast HSC Trust, Belfast, UK; 5Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK; 6Department of Molecular Genetics, Royal Devon and Exeter Foundation Trust, Exeter, UK; 7Department of Endocrinology and Diabetes, Beaumont Hospital/RCSI Medical School, Dublin, Ireland; 8Department of Clinical Medicine and Institute of Molecular Medicine, Trinity College Dublin, Trinity Centre for Health Sciences, St James’s Hospital, Dublin, Ireland; 9Royal Belfast Hospital for Sick Children, Belfast, UK; 10Endocrinology Service/Experimental Endocrinology Unit, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Mexico City, Mexico; 11Barnet General Hospital, London, UK; 12Academic Endocrine Unit, University of Oxford, Oxford, UK; 13University College London Hospitals, London, UK; 14University of Michigan, Ann Arbor, MI, USA; 15Department of Endocrinology, University Hospitals of Leicester, Leicester, UK; 16Department of Endocrinology, St James’s University Hospital, Leeds, UK; 17Institute of Anthropology, Johannes Gutenberg University, Mainz, Germany; 18North East Thames Regional Genetics Service, Great Ormond Street Hospital, London,UK; 19Trinity Biobank, Institute of Molecular Medicine, Trinity College Dublin, Trinity Centre for Health Sciences, St James’s Hospital, Dublin, Ireland; 20Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK; 21Schools of Biosciences and of Mathematics & Statistics, University of Melbourne, Australia; 22Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, UK.
In vitro effects of Imatinib on somatotrophinoma cell line
1Postgraduate Institute of Medical Education and Research, Chandigarh, India; 2Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University, London, UK.
Unique clinical picture in patients with X-linked acrogigantism
1Endocrinology, Barts and The London School of Medicine, London, UK; 2Institute of Medical Genetics, Cardiff University, Cardiff, UK; 3Molecular Genetics, University of Exeter, Exeter, UK; 4Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada; 5Endocrinology, University of Virginia, Charlottesville, USA; 6Endocrinology Service and Experimental Endocrinology Unit, Hospital de Especialidades Centro Médico Nacional Siglo XXI, IMSS, UNAM, Mexico City, Mexico; 7Imperial Centre for Endocrinology, Imperial College Healthcare NHS Trust, London, UK; 8Neurosurgery, University of Erlangen-Nürnberg, Erlangen, Germany; 9Paediatric Endocrinology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK; 10Endocrinology, PGIMER, Chandigarh, India; 11Pediatric Endocrinology & Diabetes, Princess Margaret Hospital for Children, Subiaco, Australia; 12Paediatric Endocrinology, Royal Victoria Infirmary, Newcastle, UK; 13Brain Sciences, Imperial College, London, UK.
Silencing of aryl hydrocarbon receptor protein (AIP) up-regulates the small Rho GTPase, CDC42
Barts and the London School of Medicine, Department of Endocrinology, QMUL, London, UK.
Antisense oligomer therapy directed at the GH receptor is associated with reduction in circulating GHBP levels
1The Christie NHS Foundation Trust, Manchester, UK; 2University of Sheffield, Sheffield, UK; 3University Hospital Birmingham, Birmingham, UK; 4King’s College Hospital, London, UK; 5Cardiff University, Cardiff, UK; 6St Bartholomew’s Hospital, London, UK; 7University Paris-Sud, Paris, France; 8Hopital de la Conception, Marseille, France; 9Hospital de Sant Pau, Barcelona, Spain; 10Hospital Universitario La Ribera, Valencia, Spain; 11Hospital Universitario Puerta de Hierro, Madrid, Spain; 12St. Vincent Hospital, Sydney, Australia; 13Royal Adelaide Hospital, Adelaide, Australia; 14Antisense Therapeutics, Melbourne, Australia; 15Ludwig-Maximilians University, Munich, Germany.
Developing a pituitary distress thermometer (PDT) - a means to improve patient quality of life
1University of Surrey, Guildford, UK; 2University of Plymouth, Plymouth, UK; 3Royal Sussex County Hospital, Brighton, UK.
Mortality of patients with non-functioning pituitary macroadenoma is significantly elevated: systematic analysis of 546 cases in a tertiary referral centre in the UK
1Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK; 2Department of Neuroradiology, John Radcliffe Hospital, Oxford, UK; 3Department of Neurosurgery, John Radcliffe Hospital, Oxford, UK.
The burden of AIP mutations in pituitary adenoma patients from the UK
1Barts and The London School of Medicine, London, UK; 2Royal Devon & Exeter NHS Foundation Trust, Exeter, UK; 3Oxford University Hospitals NHS Trust, Oxford, UK; 4Churchill Hospital, Oxford, UK; 5Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; 6Royal Victoria Hospital, Belfast, UK; 7Salford Royal NHS Foundation Trust, Salford, UK; 8The Christie NHS Foundation Trust, Manchester, UK; 9Guy’s Hospital, London, UK; 10Aberdeen Royal Infirmary, Aberdeen, UK; 11Royal Victoria Infirmary, Newcastle, UK; 12National Hospital for Neurology and Neurosurgery, London, UK; 13University College London Hospital, London, UK; 14Belfast City Hospital, Belfast, UK.
ACTH and gonadotrophin deficiency predict mortality in patients treated for non-functioning pituitary adenomas (NFPAs) in the UK and Republic of Ireland: long-term follow-up of 519 patients across two tertiary referral centres
1Department of Endocrinology, University Hospitals Birmingham, Birmingham, UK; 2School of Health and Population Sciences, University of Birmingham, Birmingham, UK; 3Division of Endocrinology, Beaumont Hospital and RCSI Medical School, Dublin, Ireland.
A prospective observational study of the causation and management of SIADH in a tertiary referral hospital
Academic Department of Endocrinology and Department of Chemical Pathology, Beaumont Hospital, Dublin, Ireland.
Biochemical assessment of disease activity in acromegaly; a comparison of single GH, GH day series mean, OGTT nadir and IGF-1 in 51 patients
1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK; 2Department of Medicine, University of Cambridge, Cambridge, UK; 3Department of Clinical Biochemistry, Addenbrooke’s Hospital, Cambridge, UK.
Does basal post-operative early morning cortisol measurement predict HPA axis integrity as assessed by an insulin tolerance test in patients who have undergone pituitary surgery?
1Section of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK; 2Imperial Centre for Endocrinology, Imperial College Healthcare NHS Trust, London, UK; 3Department of Neurosurgery, Imperial College Healthcare NHS Trust, London, UK.
Patient experiences of living with acromegaly in the UK
1Royal Devon and Exeter Foundation Trust, Exeter, UK; 2JSL Consulting and Associates Ltd., Devon, UK; 3Derriford Hospital, Plymouth, UK; 4Peninsula Endocrinology Network, Devon and Cornwall, UK.
The accuracy of bilateral inferior petrosal sinus cannulation and usefulness of prolactin adjustment in one Scottish centre
1South Glasgow University Hospital, Glasgow, UK; 2Wishaw General Hospital, Lanarkshire, UK; 3Glasgow Royal Infirmary, Glasgow, UK.
Current clinical management of acromegaly in the UK; a survey of endocrinologists
1Novartis Pharmaceuticals UK Limited, Frimley, UK; 2pH Associates, Marlow, UK; 3Queen Elizabeth Hospital, Birmingham, UK.
Long term follow up of patients with craniopharyngioma
Department of Endocrinology, St Bartholomew’s Hospital, London, UK.
Metabolic state in ACTH insufficient and ACTH sufficient patients with hypopituitarism not treated for growth hormone deficiency (GHD): a comparative study
1Clinic for Endocrinology, Diabetes and Metabolic Diseases Clinical Center of Serbia, Belgrade, Serbia; 2Medical Faculty, Belgrade University, Belgrade, Serbia.
Impaired quality of life in patients with acromegaly despite long-term disease control: results from a longitudinal study
1Leeds Centre for Diabetes and Endocrinology, St James’s University Hospital, Leeds, UK; 2Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; 3Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Development of a patient-reported outcome measure for pituitary surgery
1Brighton and Sussex Medical School, Brighton and Hove, UK; 2Brighton Sussex University Hospitals NHS Trust, East Sussex, UK; 3University of Surrey, Surrey, UK.
Management of pituitary apoplexy: the greater Manchester experience
1Salford Royal NHS Foundation Trust, Salford, UK; 2University of Manchester, Manchester, UK.
Loperamide-induced hypopituitarism
1Newcastle University, Newcastle upon Tyne, UK; 2Endocrine Unit, Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne, UK.
Evolution in acromegalic patients with discordant GH-IGF1 levels during medical treatment
1‘Carol Davila’ University of Medicine and Pharmacy, Bucharest, Romania; 2‘C.I. Parhon’ National Institute of Endocrinology, Bucharest, Romania.
Frontal bone recurrent ectopic craniopharyngioma after transfrontal resection: case report
1National Institute of Endocrinology, Bucharest, Romania; 2St. Marien Krankenhaus Siegengem GmbH, Siegen, Germany; 3Monza Hospital, Bucharest, Romania.
An unusual case of acromegaly
St John’s Hospital, Livingston, UK.
How common is ipilimumab-induced hypophysitis leading to cortisol deficiency?
St Helens and Knowsley Teaching Hospital NHS Trust, Mersey, UK.
TSH-secreting pituitary adenoma with negative TSH staining
Royal Preston Hospital, Preston Co., Lancashire, UK.
An unusual cause of headache in pregnancy
1Department of Endocrinology, Ealing Hospital, London, UK; 2Department of Medicine, Ealing Hospital, London, UK; 3Department of Radiology, Ealing Hospital, London, UK; 4Department of Neurology, Ealing Hospital, London, UK.
Intrasellar meningioma
St George’s University Hospital, London, UK.
Silent corticotroph adenoma presenting with severe visual loss
1Department of Endocrinology, Taunton and Somerset NHS Trust, Musgrove Park Hospital, Taunton, Somerset, UK; 2Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.